We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DLPN:NASDAQDolphin Entertainment, Inc. Analysis

Data as of 2026-03-29 - not real-time

$1.53

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Dolphin Entertainment reported a 27% year‑over‑year increase in Q4 revenue, lifting total 2025 revenue to $56.7 million. Adjusted EBITDA surged by more than 200%, reaching $2.9 million, although the company still posted a net loss. Insider confidence is evident as CEO William O’Dowd bought 3,100 shares at $1.61 each, signaling belief in the upside. The stock trades at $1.53, well below the consensus 12‑month target of $5, implying an upside of over 200%. Valuation metrics reinforce the cheapness, with a forward P/E of 4.25 versus an industry average of 16.6. Despite a strong top line, the balance sheet remains strained with a debt‑to‑equity ratio above 290, and negative earnings per share.
Technical indicators are mixed: the 20‑day SMA ($1.592) sits just above the current price, while the 50‑day SMA ($1.603) is higher, suggesting limited short‑term momentum. The RSI of 44 places the stock in a neutral zone, and the MACD histogram is negative, flagging bearish pressure. Volume has been decreasing, and 30‑day price volatility exceeds 54%, highlighting liquidity and price swing risks. The beta near 1.05 indicates modest systematic risk, but the small market cap and thin trading amplify liquidity concerns. Given the revenue growth, margin improvement, and substantial valuation gap, the medium‑term outlook leans bullish, provided cash‑flow turns positive. Investors should weigh the upside against the high debt load and ongoing cash‑flow deficits before committing capital.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram
  • Decreasing trading volume
  • Price near short‑term support level

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • 27% revenue growth YoY
  • Adjusted EBITDA up >200%
  • Valuation gap with target price $5

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Strategic AI and DealMaker initiatives
  • Potential margin expansion
  • Insider buying indicating confidence

Key Metrics & Analysis

Financial Health

Revenue Growth27.00%
Profit Margin-5.45%
P/E Ratio4.2
ROE-28.95%
ROA-0.41%
Debt/Equity294.31
P/B Ratio1.9
Industry P/E16.6

Technical Analysis

TrendNeutral
RSI43.9
Support$1.47
Resistance$1.71
MA 20$1.59
MA 50$1.60
MA 200$1.44
MACDBearish
VolumeDecreasing
Fear & Greed Index65.98

Valuation

Target Price$5.00
Upside/Downside226.80%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta1.05
Volatility54.45%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.